BRAF c.1984_1985inv ;(p.R662L)

Variant ID: 7-140449094-CT-AG


This variant was identified in 1 publication

View GRCh38 version.


Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.

Cancer Cell
Moriceau, Gatien G; Hugo, Willy W; Hong, Aayoung A; Shi, Hubing H; Kong, Xiangju X; Yu, Clarissa C CC; Koya, Richard C RC; Samatar, Ahmed A AA; Khanlou, Negar N; Braun, Jonathan J; Ruchalski, Kathleen K; Seifert, Heike H; Larkin, James J; Dahlman, Kimberly B KB; Johnson, Douglas B DB; Algazi, Alain A; Sosman, Jeffrey A JA; Ribas, Antoni A; Lo, Roger S RS
Publication Date: 2015-02-09

Variant appearance in text: BRAF: R662L
PubMed Link: 25600339
Variant Present in the following documents:
  • Main text
View BVdb publication page